435 related articles for article (PubMed ID: 8796816)
1. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
3. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu signal transduction in human breast and ovarian cancer.
Reese DM; Slamon DJ
Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217
[TBL] [Abstract][Full Text] [Related]
6. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
Ross JS; Fletcher JA
Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134
[TBL] [Abstract][Full Text] [Related]
7. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
8. Basic science of HER-2/neu: a review.
Hung MC; Lau YK
Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
[TBL] [Abstract][Full Text] [Related]
9. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
10. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
11. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma.
Jennings TS; Dottino PR; Mandeli JP; Segna RA; Kelliher K; Cohen CJ
Gynecol Oncol; 1994 Nov; 55(2):190-7. PubMed ID: 7959283
[TBL] [Abstract][Full Text] [Related]
12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
Ross JS; Fletcher JA
Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
[TBL] [Abstract][Full Text] [Related]
14. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer in the 21st century: neu opportunities and neu challenges.
Schnitt SJ
Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
[TBL] [Abstract][Full Text] [Related]
16. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
17. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
18. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP
Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
